Identifying Prostate Brachytherapy Seeds Using MRI

Overview

This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds. Researchers hope that using SWI will eliminate the need to use CT imaging to detect your implanted radioactive seeds. This study will also see if the MRI seed detection is as effective as current standard practice of seed detection (routine MRI and CT imaging). This technique would be beneficial for brachytherapy without the need to fuse the MRI and CT images, as is done currently.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2016

Interventions

  • Other: MRI Scan
    • Patient will receive an additional MRI scan in addition to their standard of care imaging

Arms, Groups and Cohorts

  • Other: MRI Scan
    • Patients will receive an extra MRI scan in addition to their routine scan.

Clinical Trial Outcome Measures

Primary Measures

  • Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce registration errors
    • Time Frame: 6 months
  • Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce planning time for the post-implant plan
    • Time Frame: 6 months
  • Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will eliminate the CT scan of the patient.
    • Time Frame: 6 months

Secondary Measures

  • Compare the differences in MR seed identification using the MR pulse sequence vs. CT images.
    • Time Frame: 6 months
    • Our goal is to perfectly match these two modalities with acceptance test of 97%. This technique would be beneficial for LDR (Low Dose Rate) Brachytherapy without need to fuse the CT and MR images and eliminate any image registration uncertainly.

Participating in This Clinical Trial

Inclusion Criteria

1. At least 18 years old 2. Histologic diagnosis of adenocarcinoma of the prostate 3. No contraindications for Pelvic body MRI 4. Patients undergoing LDR brachytherapy at PMH and scheduled for post implant analysis with CT-MR (standard at PMH) 5. Ability to provide written informed consent to participate in the study Exclusion Criteria:

1. Contraindication for Pelvic body MRI 2. Patient not willing/consenting for this study

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Health Network, Toronto
  • Collaborator
    • Princess Margaret Hospital, Canada
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Saibishkumar Elantholiparameswaran, MD, Principal Investigator, University Health Network, The Princess Margaret

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.